Misoprostol Versus Active Management of Labour in CS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-28

Study Completion Date

2018-03-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Several treatment strategies are emplemented to prevent post delivery hemorage and decreasing maternal morbidity and mortality .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intrauterine Misoprostol Versus Rectal Misoprostol in Reducing Blood Loss During Cesarean Section

NCT03723031

Hemorrhage, Postpartum

UNKNOWN PHASE2

Preoperative and Postoperative Sublingual Misoprostol for Prevention of Postpartum Blood Loss in Cesarean Section

NCT03591913

Postpartum Hemorrhage

COMPLETED PHASE4

Misoprostol+Oxytocin vs. Carbetocin in CS

NCT02786992

Cesarean Section

COMPLETED PHASE2/PHASE3

Misoprostol Before and After Cesarean Section

NCT03463070

Post Partum Hemorrhage

UNKNOWN PHASE3

The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS

NCT03680339

Post Partum Hemorrhage

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Many approved drugs are used in prophylaxis against postpartum hemorage from these medications are the (syntocinon combined with methergine ) that are known as active management of labour drugs .

Moreover there is misotac , that also guards against postpartum hemorage .

All these medications act in a different way to cause uterine contraction post delivery to prevent uterine atony .

-Here we are comparing the additive value of misotac intrauterine to syntocinon and methergine in comparison to the usually used syntocinon plus methergine .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cesarean Section

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Extra medication group

-Procedure : Giving misoprostol plus syntocinon during CS

this group in which prevention of uterine atony is made by intrauterine misoprostol plus the usual syntocinon and using extra uterotonic drugs when needed ; methergine , carboprost

Group Type ACTIVE_COMPARATOR

Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine

Intervention Type DRUG

medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost

Active management of labour group

* Procedure: Giving syntocinon during cesarean section
* this group in which prevention of uterine atony is made by the usual active management of labour syntocinon and using extra uterotonic drugs when needed ; methergine , carboprost

Group Type ACTIVE_COMPARATOR

Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost

Intervention Type DRUG

medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine

medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost

Intervention Type DRUG

Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost

medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DrugsMisoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine , carboprost drugs ( syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • All patients included in this research were aged 18-42 years, pregnant 37 weeks till 42 weeks

* no medical disorders with pregnancy e.g DM, HTN. All patients were subjected to full history taking, examination.

Exclusion Criteria

* The following patients were excluded , GA before 37 weeks or after 42 weeks , medical disorders with pregnancy eg. DM with pregnancy, HTN with pregnancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

42 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes